Vanda Pharmaceuticals | VNDA - Assets


Vanda Pharmaceuticals reported $488.95M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
J&J USD 201.06B 167M Jun/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 10.96B 527M Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 129.06B 1.04B Jun/2026
Takeda JPY 15.66T 210.16B Jun/2026
Teva Pharmaceutical Industries USD 39.86B 183M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Veracyte USD 1.49B 49.97M Jun/2026